Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie announced significant findings on its investigational drugs at the UEG Week Virtual 2021, running from October 3-5. The company will present 13 abstracts, including late-breaking studies on risankizumab (SKYRIZI) for Crohn's disease and upadacitinib (RINVOQ) for ulcerative colitis. Key results from pivotal Phase 3 studies showed upadacitinib's efficacy in symptom control and clinical remission at week 52. Additionally, data highlighting the quality of life improvements for IBD patients will be shared. AbbVie aims to enhance treatment standards in IBD management.
AbbVie has shared new Phase 3 data analyses from the KEEPsAKE-1 and KEEPsAKE-2 studies, detailing the efficacy of risankizumab (SKYRIZI®) in treating adults with active psoriatic arthritis over one year. At the 2021 EADV Virtual Congress, results showed significant patient responses, with 70% and 58% achieving ACR20 response in KEEPsAKE-1 and KEEPsAKE-2, respectively. Furthermore, 76% achieved resolution of dactylitis. The safety profile remained consistent, with no new adverse findings reported. These developments underscore AbbVie's commitment to enhancing treatment options for psoriatic arthritis.
AbbVie (NYSE: ABBV) presented new analyses of its medication RINVOQ® (upadacitinib) for treating moderate to severe atopic dermatitis at the EADV Virtual Congress. Key findings include that over 61% of patients on RINVOQ 30 mg achieved EASI 75 at week 16 compared to 11% on placebo, irrespective of demographics. Additionally, RINVOQ demonstrated superior efficacy against dupilumab in four body regions at week 16. The safety profile remained consistent with previous studies, with acne as the most common adverse event.
AbbVie (NYSE: ABBV) announced FDA approval for QULIPTA™ (atogepant), the first oral CGRP receptor antagonist for preventing episodic migraines in adults. Supported by robust clinical data, QULIPTA demonstrated significant reductions in monthly migraine days and was well tolerated among nearly 2,000 patients in trials. It aims to alleviate the substantial disability caused by migraines, which affect over 39 million people in the U.S. QULIPTA will be available in October 2021, complementing AbbVie's migraine treatment portfolio.
Summary not available.
AbbVie (NYSE: ABBV) announced it will present 27 abstracts at the 30th EADV Congress from September 29 to October 2, 2021. Highlights include analyses on RINVOQ (upadacitinib) for atopic dermatitis and new data on SKYRIZI (risankizumab) for psoriasis and psoriatic arthritis. Key findings will come from Phase 3 trials, including a head-to-head study of RINVOQ vs. dupilumab, showcasing safety and efficacy. This reinforces AbbVie's commitment to enhancing care for chronic inflammatory diseases.
AbbVie announced the submission of an application to the FDA for risankizumab-rzaa, a new treatment for moderate to severe Crohn's disease in patients aged 16 and older. This drug, an IL-23 inhibitor, is backed by data from three Phase 3 trials: ADVANCE, MOTIVATE, and FORTIFY. In these studies, patients treated with risankizumab-rzaa showed significantly greater clinical remission and endoscopic response compared to placebo. The therapy aims to address the unmet need for lasting remission in Crohn's patients, as highlighted by AbbVie’s senior VP of research.
AbbVie has submitted applications to the FDA and EMA for upadacitinib (15 mg, 30 mg, and 45 mg) for treating adults with moderately to severely active ulcerative colitis. These submissions are based on positive results from two Phase 3 induction studies and one maintenance study, where upadacitinib showed significant improvement in clinical remission compared to placebo. Additionally, the safety profile was consistent with existing data, with no new risks identified. This treatment could provide a new option for patients who have not responded adequately to current therapies.
AbbVie and REGENXBIO announced a partnership to develop RGX-314, a gene therapy for wet age-related macular degeneration (AMD) and diabetic retinopathy (DR). REGENXBIO will complete ongoing trials, while AbbVie leads global development and commercialization. AbbVie will pay REGENXBIO $370 million upfront, with potential total payments of up to $1.38 billion based on milestones. They will share profits from U.S. sales equally, with AbbVie paying tiered royalties internationally. The deal is expected to close by the end of 2021, contingent on regulatory approvals.
AbbVie Inc. (NYSE: ABBV) has declared a quarterly cash dividend of $1.30 per share, payable on November 15, 2021, to stockholders of record by October 15, 2021. Since its inception in 2013, AbbVie has increased its dividend by 225% and is recognized as a member of the S&P Dividend Aristocrats Index, highlighting its commitment to consistent annual dividend increases over at least 25 consecutive years.